Market revenue in 2023 | USD 47.6 million |
Market revenue in 2030 | USD 76.7 million |
Growth rate | 7% (CAGR from 2023 to 2030) |
Largest segment | Targeted therapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy |
Key market players worldwide | Novartis AG ADR, Pfizer Inc, Merck KGaA, Janssen Pharmaceuticals, Celgene, Roche Holding AG, AstraZeneca PLC, AbbVie Inc, Bristol-Myers Squibb Co, Macrogenics Inc, Celldex Therapeutics Inc, Sanofi SA, Amgen Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer drugs will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 64.29% in 2023. Horizon Databook has segmented the Denmark breast cancer drugs based on chemotherapy, immunotherapy, targeted therapy, hormonal therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Denmark breast cancer drugs, including forecasts for subscribers. This country databook contains high-level insights into Denmark breast cancer drugs from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account